Neil Iyengar: New Report on GLP1 Receptor Agonist Use in Breast Cancer Survivors
Neil Iyengar, Co-Director of Breast Oncology and Director of Cancer Survivorship at Emory University’s Winship Cancer Institute, shared a post on LinkedIn:
“Here we report initial/preliminary observations on GLP1 receptor agonist use in breast cancer survivors. This medical weight loss therapy prevented weight gain and induced modest (4-6%) weight loss, particularly during hormone therapy.
Weight gain is a major problem during adjuvant treatment for breast cancer. While we have seen larger magnitudes of weight loss with some types of lifestyle (diet/exercise) interventions, having another tool for weight loss is helpful.
We need (and are designing) clinical trials to determine the optimal dosing, scheduling, and use of medical weight loss therapy in cancer survivors (partially obesity-related cancers), and how best to integrate medical weight loss with lifestyle interventions.”
Title: GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Authors: Sherry Shen, Bethina Liu
Read The Full Article at Cancer Network.
More posts featuring Neil Iyengar on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023